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Untilrecentlycancermedicaltherapywaslimitedtochemotherapythatcouldnotdiﬀerentiatecancercellsfromnormalcells.More
recently with the remarkable mushroom of immunology, newer tools became available, resulting in the novel possibility to attack
cancerwiththespeciﬁcityoftheimmunesystem.Hereinwewillreviewsomeoftherecentachievementofimmunotherapyinsuch
aggressivecancersasmelanoma,prostaticcancer,colorectalcarcinoma,andhematologicmalignancies.Immunotherapyoftumors
has developed several techniques: immune cell transfer, vaccines, immunobiological molecules such as monoclonal antibodies
that improve the immune responses to tumors. This can be achieved by blocking pathways limiting the immune response, such
as CTLA-4 or Tregs. Immunotherapy may also use cytokines especially proinﬂammatory cytokines to enhance the activity of
cytotoxic T cells (CTLs) derived from tumor inﬁltrating lymphocytes (TILs). The role of newly discovered cytokines remains to be
investigated. Alternatively, an other mechanism consists in enhancing the expression of TAAs on tumor cells. Finally, monoclonal
antibodies may be used to target oncogenes.
1. Different Antigenicityof Tumors
An important role of the immune system is to identify and
eliminate tumors. Transformed cells of tumors express anti-
gens that are not found on normal cells; these antigens are
called tumor-associated antigens (TAAs). The immune sys-
tem recognized these antigens as not self and mounts an
immune response against tumor cells. However, tumors de-
velop several mechanisms to escape immune recognition.
For instance, when T cells interact with tumors, they may
deliver several potential inhibitory signals, including lack of
proper costimulatory activity by tumor cells and induction
of immunosuppressive Tregs [1, 2].
Intherecentyears,speciﬁcantigeniccharacterizationhas
permitted us to study an increasing number of tumors, in
particular regarding their ability to escape from immune re-
sponse and to downmodulate TAA expression and secreting
inhibitory molecules. This has resulted in the identiﬁcation
of tumors that elicit diﬀerent immune responses: (1) strong
immunogenic tumors, such as melanoma and renal cell car-
cinoma, (2) the majority of tumors, however, are poorly
immunogenic tumors: these include, for instance, colorectal
cancer,hepatocellularcarcinoma,pancreaticcarcinoma,pro-
state carcinoma, lymphomas and leukaemias, and others [3,
4].
The tumor-associated antigens (TAAs) expressed by tu-
mors have several sources.
(a) Some are derived from oncogenic viruses like human
papillomavirus, which causes cervical cancer [5]. The
HPV oncoproteins E6 and E7 have crucial roles in
variousstepsofcarcinogenesis,inducing degradation
of p53 and destabilization of pRb. Several clinical
trials show that recombinant HPV vaccines are safe
and eﬀective in preventing persistent infection of
HPV and associated anogenital lesions. Thus, pro-
phylacticHPVvaccinationmaybeanidealpreventive
methodforotherHPV-associatedcancers.Therefore,
vaccine against papillomavirus may be considered a
very eﬀective antitumor agent [6–8].
(b) Other TAAs are cellular proteins usually present in
the human body that are overexpressed or aberrantly
expressed in tumor cells; furthermore, others TAAs
are also products of mutated genes.2 Clinical and Developmental Immunology
(c) In addition, TAAs may also be the products of onco-
genes or mutated oncosoppressors.
The most useful response of the immune system against
tumors is to kill the abnormal cells using CTLs, which
abound among TILs [9, 10]. TAAs are presented on MHC
class I molecules. This allows CTLs to recognize the tumor
cellasabnormal.NKcellsalsokilltumorcellsbycytotoxicity,
especially if the tumor cells have fewer MHC class I mol-
ecules on their surface than normal; this being a common
phenomenon in tumors.
Upon activation, CTLs express on their surface the death
activatordesignatedFasligand(FasL)andtheengagementof
Fas/FasL pathway lead to mediated apoptosis of cancer cells
[11, 12].
Despite the activity of the immune system, clearly, tu-
mors may evade the immune system and become clinically
evident. Tumor cells often have a reduced number of MHC
class I molecules on their surface, thus avoiding detection by
killer T cells.
An important challenge in cancer immunotherapy is the
identiﬁcation of eﬀective strategies for enhancing its clinical
eﬃcacy. One approach is based on adjuvants, capable of
breaking tolerance against TAAs. Interferons-alpha (IFN-
alpha) are pleiotropic cytokines belonging to type I IFNs,
extensively used in the treatment of patients with some
types of cancer and viral disease. IFN-alpha can increase the
expression of surface antigens enhancing the immune re-
sponse, acting as an eﬀective adjuvant in cancer immun-
otherapy [13, 14]. In melanoma it has been demonstrated
that IFN-alpha increases the accumulation of gp100-speciﬁc,
IFN-gamma-secreting CD8+ T cells in the tumor, demon-
stratingitseﬃcacyasanadjuvantforpeptidevaccinationand
giving insight into its mechanism of action. This provides a
rationale for clinical trials in which vaccination is combined
with IFN-alpha therapy for melanoma [15]. In addition,
IFN-alpha can promote the diﬀerentiation and activity of
host immune cells. Notably, a special interest is currently
focused on the use of dendritic cells (DCs) generated in the
presence of IFN-alpha (IFN-DC) for the preparation of an-
ticancer vaccines. An additional approach for enhancing the
response to immunotherapy relies on its combination with
chemotherapy [16].
Here we will brieﬂy discuss the immunobiology of tu-
mors. Because the topic is too vast for this paper, we will
discuss two tumors: melanoma as an example of strong im-
munogenic tumor and colorectal cancer as an example for
poorly immunogenic tumors.
1.1. A Strong Immunogenic Tumor: Melanoma. Malignant
melanoma is one of the most aggressive malignancies in hu-
man and is responsible for almost 60% of lethal skin tumors.
Therapy with IFN-alpha 2b, the only agent approved in the
USA for adjuvant use in high-risk melanoma patients, has
not shown consistent overall survival beneﬁt in randomized
trials and is associated with considerable toxicity. Melanoma
is one of the ﬁrst tumors that have been associated to the
presence of local cellular inﬂammation. The description of
a lymphocytic inﬁltration of primary cutaneous melanoma
conﬁrmed Virchow’s suggestion of a direct connection be-
tween inﬂammation and cancer. The past 30 years have ac-
cumulated considerable evidence that many tumors elicit a
signiﬁcant immune response, and a more favourable prog-
nosis is correlated with the levels of TILs [17]. Nevertheless,
although tumor microenvironment TILs include tumor-
reactive T cells, melanoma can escape the immune system
and continue to grow and metastasize [1]. Studying these
mechanismsofimmuneescapeofthetumorwillimprovethe
strategies to overcome obstacles to successful immunother-
apy of tumors.
Melanoma is characterized by the expression of several
TAAs, which can be recognized by T cells, resulting in a
strong immunological response to the tumor. These TAAs
include gp100, Melan-A/Mart-1, tyrosinase, MAGE-A1, and
NY-ESO [1, 18].
Recent data have demonstrated that combined thera-
peutical approach with chemotherapy and cancer vaccines
may have positive eﬀects in the treatment of advanced and
metastatic tumors. Chemotherapy, alone or with the associ-
ation of cancer vaccine, can improve the expression of TAAs
and induce enhancement of the cancer-reactive CD8+ cyto-
toxic T cells (CTLs) [16]. Speciﬁc topoisomerase inhibitors
canaugmentmelanomaantigensproduction,suggestingthat
acombinationofchemotherapyandimmunotherapymaybe




Tregs mediate their immunosuppressive action also by the
expression of the negative costimulatory receptor CTLA-4.
Furthermore, in the last years, the identiﬁcation of,
somaticmutationsinthegeneencodingtheserine-threonine
protein kinase B-RAF (BRAF) in the majority of melanomas
has resulted in an opportunity to test oncogene-targeted
therapy for this disease. Patients with advanced metastatic
melanoma have been treated with PLX4032 (Plexxikon;
RG7204, Roche Pharmaceuticals), a potent inhibitor of
BRAF with the V600E mutation; this treatment resulted
in complete or partial tumor regression in the majority of
patients [20, 21].
Melanomas share initiating genetic alterations such as
oncogenic mutations in BRAF and NRAS and often show
recurrentpatternsofchromosomalaberrations.Alterationof
cell cycle proteins (e.g., cyclin D1, pRb, and p16) has a role
in transformation and progression in melanocytic tumors.
Higher expression of PAR-1 (protease-activated receptor-1)
is seen in melanoma cell lines and tissue specimens [22].
Upregulation of PAR-1 mediates high levels of Cx-43
(gapjunctional intracellular communication molecule con-
nexin) expression. This molecule is involved in tumor cell
diapedesis and attachment to endothelial cells [23]. Protein
kinase C (PKC) mediates signals for cell growth and is
a target of tumor-promoting phorbol esters in malignant
transformation [24]. Downregulation of E-cadherin and
upregulation of N-cadherin may be seen in melanoma cells.
Such shift of cadherin proﬁle may have a role in uncon-
trolled proliferation, invasion, and migration. Other studies
demonstrated the association of vascular endothelial growthClinical and Developmental Immunology 3
factor (VEGF) and VEGF-receptor family with progression
and melanoma metastasis [22].
Eﬀective cancer immunotherapy is dependent on the
presence of large number of antitumor lymphocytes with
appropriate homing and eﬀector functions that enable them
to seek out and destroy cancer cells in vivo.A d o p t i v ec e l l
therapy (ACT) refers to an immunotherapy approach in
which antitumor lymphocytes are identiﬁed and grown ex
vivo and then infused into the cancer patients, often along
with vaccines or growth factors that can augment the in
vivo impact of the transferred cells. ACT with autologous
tumor inﬁltrating may mediate durable complete responses
in patients with metastatic melanoma [25].
1.2. A Poorly Immunogenic Tumor: Colorectal Cancer (CRC).
Colorectal cancer (CRC) is one of the leading causes of death
in the Western world. Immunotherapy could play a crucial
roleinpatientswithadvanceddiseaseatpresentationpermit-
tingtumorregressionorpossiblyclearance.Despiteadvances
in research and treatment modalities, CRC still accounts for
around half a million deaths yearly worldwide. Traditional
and even newer pharmaceutical therapeutic regimens are
limited in terms of tolerance, eﬃcacy, and cross-resistance.
Additional non-cross-resistant therapies with nonoverlap-
ping toxicities are needed to improve the outcome for pa-
tients with CRC. Cancer vaccines, designed to activate
immune eﬀectors (T cells and antibodies) to prevent recur-
rence or treat advanced cancers, have now demonstrated
clinical beneﬁt [26].
Bonertz et al. have found that in CRC Tregs T-cells re-
sponse is addressed against a limited repertoire of TAAs,
which include p53, carcinoembryonic antigen (CEA), Her2/
neu, and heparanase pp1 [27].
Colorectal tumor cells frequently express CEA which
correlates with the state of the tumor, augmenting its ex-
pression in advanced phases. CEA is considered a clinical
marker of this tumor, with utility in the diagnosis, prognosis
and followup of the disease [28, 29]. Some authors have
used anti-CEA antibodies tagged with radioactive Yttrium-
90 [30] against CEA-expressing metastatic malignances or
combined with antivascular antigens, like combretastatin
andbevacizumab(anti-VEGF),orwithgemcitabine[31–33].
Moreover, in recent years it has been shown that CRC can
express other antigens, such as extracellular surface marker
CD55 [34] and the oncofetal antigen 5T4. This latter is a
surface glycoprotein expressed on a variety of human adeno-
carcinomas, including CRC, and plays an important role in
tumor progression and metastasis. The expression patterns
andfunctionalrolein themetastatic processsuggestthat5T4
is a good target for vaccine development. A modiﬁed vaccine
virus Ankara (MVA) encoding human 5T4 (designated
TroVax) demonstrated therapeutic eﬀects in murine tumor
models and human T cells recognized 5T4 epitopes in
an HLA-restricted manner. TroVax vaccine has been eval-
uated in clinical trials targeting patients with colorectal
cancer of advanced stage (IV stage), renal cell carcinoma,
and hormone refractory prostate cancer [35]. Results from
clinical trials on metastatic colorectal cancer demonstrate
that MVA-5T4 is safe and immunogenic as a monotherapy
and in combination with standard-of-care therapies. MVA-
5T4 induced potent and sustained immune responses in
approximately 95% of tested patients. With its minimal side
eﬀects and ability to produce immune responses, MVA-5T4
is a promising addition to cancer therapy [36]. Moreover,
preliminary results showed signiﬁcant associations between
5T4-antibody responses and overall survival in patients with
CRC. The 5T4-speciﬁc antibodies were present at higher
levels in cancer patients compared with healthy donors and
increased signiﬁcantly after treatment with MVA-5T4 [37].
Furthermore, CRC can express oncogenes; in particular,
KRAS mutations occur in almost 40% of CRC patients.
KRAS is a cellular signalling eﬀe c t o rd o w n s t r e a mf r o mt h e
EGF/EGFR pathway. KRAS mutations are common in color-
ectal, ovarian, and lung adenocarcinomas. There have been
recent attempts to quantify KRAS mutation and predict
responses to treatment using an EGFR inhibitors (cetuxi-
mab) [38].
In addition, studying on TILs has permitted us to
diﬀerentiate between the immune cellular populations: Tregs
and Th17 cells are involved in the pathogenesis and the
progressionandproliferationofCRCmalignantcells.Inpar-
ticular Tregs and Th17 cells are correlated with a poor prog-
n o s i so fC R Ca n dw i t ha d v a n c e dt u m o r s[ 39]. According to
their immune inhibitory function, Tregs depletion results in
stronger TAA-speciﬁc immune response [27].
2.Biology of the ImmuneResponse toTumors
2.1. Immune Pathways That Can Potentially Limit Tumor Ex-
pansion
2.1.1. Mechanisms of Action in Tumor Vaccines: DCs, CTLs,
and Humoral Response. The discovery of high number of
tumor-inﬁltrating lymphocytes (TILs) with skewed tumor-
speciﬁc TCR expression has promoted the development of
both adoptive immunotherapy with transfer of TAA-primed
TILs into patients and vaccine-based antitumor therapy
[1, 40]. CTLs mediate tumor destruction by the release of
perforin [41] and granzymes or by the activation of the Fas-
/FasL- mediated apoptosis [42].
Therapeutic tumor vaccines have two main objectives:
priming Ag-speciﬁc T cells and reprogramming memory T-
cells (i.e., a transformation from one type of immunity to
another, e.g., regulatory to cytotoxic). Dendritic cells are es-
sential in the generation of immune responses, and as such
represent targets and vectors for vaccination [43]. The main
goal of tumor vaccine therapy is the production of mature
dendritic cells (DCs, the most specialized APCs) able to
stimulate an antigen-speciﬁc T-cells response in vivo [44]. In
classical protocol DCs are activated and loaded with TAAs or
transfected with RNA-encoding tumoral epitopes and then
transferred to tumor-bearing hosts [45, 46]. Notably, most
antigens expressed on tumor cells are self antigens and may
result in poor antigenicity due to negative selection of high-
avidityautoreactiveT-cellsubsets;moreoverantigensexpres-
sion depend on the proteolytic processing by immunopro-
teasomes and diﬀerential binding to allelic MHC variants4 Clinical and Developmental Immunology
leading to the hiding of “cryptic” speciﬁc epitopes [47].
Therefore the antigen presentation may be diﬀerent in dif-
ferent cells, and a selection of proper antigenic peptides may
be useful to mediate eﬃcient killing of cancer cells [47].
2.2. Immunological Pathways That Can Limit the Immune Re-
sponses
2.2.1. The Role of Tregs. The heterogeneity of CD4 cells has
been described in the past [48] ,b u to n l yr e c e n t l yaC D 4
T-cell subpopulation with regulatory function (Tregs) has
been characterized functionally. Regulatory T cells (Tregs)
represent about 5–10% of peripheral CD4+ T cells; they
are characterized by the ability to suppress T-cell responses.
If this function is impaired, the host will be exposed to
dysfunctions in self-tolerance. Several diseases have been
linked to defective Treg activity including type I diabetes,
allergy, and other autoimmune diseases [39, 49–51].
In tumors, several studies suggested a direct correlation
between adverse prognosis and presence of Tregs in periph-
eral blood as well in TILs and in draining lymph nodes of
diﬀerent tumors [52].
Tregs express a number of chemokine receptors such as
CCR2, CCR4, CCR5, CCR7, CCR8, and CXCR4 and are able
to migrate in response to a variety of chemokines such as
CCL22, CCL17, CCL1, and CCL4 [53–55]. Tregs may be re-
cruits to the tumor site by the chemokine CCL22 produced
by the tumor cells and tumor-associated macrophages
(TAMs). Tregs accumulated via CCL2-CCR4 recognize tu-
mor-associated immunogenic self-antigens (self-Ags) and
proliferate [52]. Moreover, a recent study on breast cancer
showed that the hypoxia environment drives the Tregs re-
cruitment through both CXCL12 production by tumor cells
and hypoxia-induced CXCR4 expression in Tregs [56].
Moreover, Tregs selectively recruited within the tumor
site will be activated by mature DCs likely through TAA;
therefore, Tregs induce T-cell suppressions in an antigen-
selective manner [52]. Indeed it is also clear that vaccination
withsomeoftheseepitopes,administeredwithorwithoutan
adjuvant or presented by ex vivo cultured antigen-presenting
cells (APCs), can induce humoral and CTL antitumor re-
sponses in some cases [57].
It has been reported that immunosuppressive factors
produced in the growing tumor environment, such as TGF-
beta, IL-6, and IL-10, created an immunosuppressive envi-
ronment. Therefore, both the tumor cells (by their expres-
sion of tumor antigens and production of these factors) and/
or the TAMs may act via promoting the antigen-activated
Tc e l l st od i ﬀerentiate and proliferate into Treg cells [58].
Tregs suppression may therefore impair cancer immuno-
therapies [52]. Therefore a clear understanding of the mech-
anisms of action by Tregs in tumor immunity is needed to
establish a useful tumor vaccine or immunotherapy [59, 60].
Tregs are highly speciﬁc for antigens, suggesting that they
exert T-cell suppression in an antigen-selective manner [27].
Recentdata,conﬁrmingthehighpresenceofTregswithin
TILs in the tumor site and in the tumor-draining lymph
nodes, however, has demonstrated that regulatory T cells in
TILs donot originate by conversion of T-conventional cells
(T-conv). Tregs arise from diﬀerent populations with unique
TCR repertoires. Enrichment of Tregs within TILs most
likely, therefore, reﬂects diﬀerences in the way that Treg and
T-conv cells are inﬂuenced by the tumor microenvironment.
Elucidating the nature of these inﬂuences may indicate how
the balance between tumor-inﬁltrating Treg and T-conv cells
can be manipulated for therapeutic purposes [61].
2.2.2. The Role of CTLA-4 and PD-1. T-cell activation and
inhibition are regulated by signalling of several molecules in-
cludingCD28thatprovidescostimulation,CTLA-4(CD152)
that binds to the same ligands as CD28, but has more aﬃnity
and delivers an inhibitory signal, and programmed death-
1 (PD-1) that may be involved in tumor evasion. All these
molecules have a potential role in immunotherapy [39].
Remarkably, CTLA-4 has more aﬃnity than CD28 for
its ligands and can trigger T-cell anergy. CTLA-4 delivers
inhibitory signals to T cells blocking their eﬀector functions
throughdiﬀerentmechanismsincludingdiminishingofTCR
signalling, blocking cell cycle progression, and reducing IL-2
production [39].
Also PD-1 seems to be involved in immune evasion, and
its expression is reported in melanoma TILs contributing to
their impaired antitumor responses [62].
2.2.3. The Role of Cytokines in Regulation of Tumor Antigens.
Tumors can mediate their ability to escape immune recog-
nition also secreting immunosuppressive cytokines, such as
IL-10 and TGF-beta [63]. Furthermore Tregs can downmod-
ulate immune response by cytokine secretion; these include
IL-10, TGF-beta, and the discovered novel IL-35 [64–68]. IL-
35 has been shown to be constitutively expressed by regula-
tory T cells and contributes to their suppressive activity. IL-
35 is an important mediator inducing CD4+CD25+ T-cell
proliferation and IL-10 production [69].
Recent data have demonstrated also a relation between
cytokines and vitamins. In particular, vitamins A, D, and E
modulateTregfunctionandIL-10andTGF-betaproduction,
involving the immune response mechanisms [70].
Moreover, in addition to the immune cells, also tumors
can directly secrete immunosuppressive cytokines, further
permittingthemtoevadetheimmuneresponse.Forexample
melanoma secretes oncostatin M (OSM), which transmits
its signal via the gp130 cell surface receptor, resulting in
the selective downmodulation of the melanocyte lineage
antigens: Melan-A/MART-1, gp100, tyrosinase, tyrosinase-
related proteins 1 and 2, and the M isoform of microphthal-
mia transcription factor [71]. On the other side it is impor-
tant to underline that TAAs expression can be modulated
in both directions. IFN-beta is an additional stimulus to
TAAs expression in melanoma, including Melan-A/MART-
1, gp100, and MAGE-A1, permitting an improve of immune
response to melanoma cells [1, 18].
2.2.4. The Role of Heat Shock Protein 90 (HSP90). In recent
years some data have revealed that the molecular chaperone
Heat Shock protein 90 (HSP90) is involved in several
condition, including cancer. Hsp90 regulates the traﬃckingClinical and Developmental Immunology 5
of proteins in the cell, under stressful conditions, stabilizes
its client proteins, and provides protection to the cell against
cellular stressors such as in cancer cells. Through its role
in regulating the conformation, stability, and function of
several key, oncogenic client proteins, HSP90 contributes in
maintaining malignant transformation and in increasing the
survival, growth, and invasive potential of cancer cells.
HSP90-inhibitors, such as geldanamycin and its ana-
logue 17-allylamino-17-demethoxygeldanamycin (17-AAG,
tanespimycin), determine suppression of MAPK pathway
in malignant cells and may become new anticancer agents
[72, 73]. Moreover, Banerji et al. have shown a correlation
between oncogenic BRAF and NRAS mutations, frequently
associatedwithmalignantmelanoma,andtheHSP90.Infact
NRAS mutations are stabilized by the molecular chaperone
HSP90andtheyaredepletedbytheHSP90inhibitor17-AAG
[74]. In addition inhibitors may also upregulate TAAs [75].
3.ClinicalApproachto
Immunotherapy of Cancer
The increased understanding of the mechanisms of immun-
oregulation has suggested new strategies to design more ef-
fective cancer immunotherapies.
3.1. Vaccines: Prostate Cancer and Melanoma. Cancer vacci-
nation is a kind of immunotherapy that relies on speciﬁc
priming of the immune system in order to stimulate prin-
cipally adaptive immunity against vaccine component, in
contrast to nonspeciﬁc immunotherapy where the adminis-
teredagenttriestoenhancetheinnateimmunity(e.g.,Bacille
Calmette Gu´ erin). Early attempts to develop eﬀective cancer
vaccines had limited success due to the failure to identiﬁcate
suitable target antigens, to mitigate the immunosuppressive
environment and generate an eﬀective immune response
[76]. However, an improvement in our understanding of the
immunesystemandtumorimmunity,inparticular,hasfacil-
itated the development of more promising vaccine strategies
[77, 78].
Diﬀerent vaccination strategies have been investigated
including the use of whole-tumor cells or lysates, dendritic
cells,peptide-baseapproach,recombinantproteins,andviral
and DNA delivery vectors. Since antigens are poorly immu-
nogenic by themselves, vaccines generally require the inclu-
sion of potent immunoadjuvants to induce antitumor re-
sponses and a delivery system to eﬀectively present the an-
tigen to the immune system [77].
Sipuleucel-T represents the ﬁrst cancer vaccine approved
bytheUSFoodandDrugadministrationforthetreatmentof
metastatic hormone-refractory prostate cancer. Sipuleucel-
T consists of autologous peripheral-blood mononuclear
cells including antigen-presenting cells (APCs) that have
been activated ex vivo with a recombinant fusion protein
(PA2024) which contains prostatic acid phosphatase fused
to granulocyte-macrophage colony-stimulating factor [79].
In a double-blind, placebo-controlled, multicenter phase III
trial, patients with metastatic castration-resistant prostate
cancer who received Sipuleucel-T had a prolonged overall
survival (median survival 25.8 months in the sipuleucel-T
arm versus 21.7 in the placebo group) showing a relative
reduction of 22% in the risk of death as compared with
placebo arm; also the rate of 3-year survival was increased
forpatientsreceivingSipuleucel-T(31.7%)ascomparedwith
those receiving placebo (23%). In particular, patient in the
Sipuleucel-T group who had an antibody titer of more than
400 against PA2024 or prostatic acid phosphatase at any
time after baseline lived longer than did those who had an
antibody titer of 400 or less (P<0.001 and P = 0.08, resp.).
Adverse events that were more frequently reported in the
Sipuleucel-T group included chills, fever, and headache [79].
Several vaccines against melanoma antigens were tested
in early clinical trials demonstrating a clinical beneﬁt, but
when tested in prospective randomized trials for advance
melanoma, they failed to improve progression-free or overall
survival compared with chemotherapy. The ﬁrst evidence of
clinical beneﬁt of vaccination for patients with metastatic
melanoma came from a prospective randomized phase III
trial, conducted with stage IV or locally advanced stage III
cutaneous melanoma, HLA A0201+ patients, without brain
metastases who received high-dose IL-2 (720.000IU/kg/
dose) as the control group and a gp100 peptide containing a
modiﬁed209-217(210M)epitope+montanideISAfollowed
by high-dose IL-2 as the experimental arm [80]. The mod-
iﬁed g209–217 peptide (referred to as g209-2M) presents
a methionine replacing the natural threonine at position
2; it bounds to the HLA-A2 molecule with greater aﬃnity
than the unmodiﬁed peptide, and it was shown to have
an increased ability to generate melanoma-reactive CTLs.
Responseratewassigniﬁcantlyimprovedintheexperimental
arm as compared with control group (22.1% versus 9.7%
(P = 0.0223),andalsoprogression-freesurvivalfavouredthe
gp100-immunized patients compared to those treated with
IL2 alone (2.9 months versus 1.6 months, P = 0.01). Over-
all survival was longer in the experimental group, but the
diﬀerence was not signiﬁcant (17.6 versus 12.8 months, P =
0.0964).
Other vaccines containing multiple tumor-associated
antigens including MAGE proteins, MART-1/MelanA, and
gp100 were tested in a phase I/II trial in patients with
advanced melanoma with evidence of clinical activity and
durable responses [81]. Also vaccines containing dendritic
cells pulsed with melanoma-associated antigens or autolo-
gous lysates [82], or electroporated with mRNA encoding
CD40 ligand, constitutively active toll-like receptor 4, and
CD70, are under investigations in metastatic melanoma pa-
tients [83].
A vaccine containing a tumor-associated antigen such as
MAGE-A3 was also tested in a phase II study for patients
withnon-small-celllungcanceraftercompleteresectionwith
improvement in disease-free and overall survival; on the
basis of these results, a phase III study with this vaccine was
initiated in 2007 and is currently ongoing [84].
Other vaccines produced promising phase III data such
as vitespen, an autologous adjuvant vaccine for patients at
high risk of recurrence after nephrectomy for renal cell car-
cinoma [85] and Biovaxid, an idiotype vaccine for patients
with follicular lymphoma in ﬁrst complete remissions [86].6 Clinical and Developmental Immunology
Human telomerase reverse transcriptase (hTERT), the
rate-limiting subunit of the telomerase complex, is another
attractive target for cancer vaccination since telomerase is
highly expressed in almost all cancer forms, while the expres-
sion in normal tissues is restricted. Phase I/II trials in ad-
vanced pancreatic and pulmonary cancer patients after vac-
cination with GV1001, a 16-aminoacids-peptide of hTERT
sequence, have demonstrated some speciﬁc and durable T-
cell responses, associated to a prolonged survival, without
clinically important toxicity [87, 88].
3.2. Biological Drugs and Their Combination with Cancer
Chemotherapy. In contrast to conventional chemotherapy,
immunotherapy of tumors has raised the hope of a more
speciﬁc therapeutical approach in oncology. In fact, immun-
otherapy, targeting TAAs, has permitted to use novel more
speciﬁc molecules in cancer therapy.
As discussed above, biological therapies can also stimu-
late the immune response against cancer. In addition, as we
will see, biological therapy can interfere with tumor blood
vessel formation therefore blocking its ability to develop.
Insomeconditions,biologicalagentsmayalsobeadmin-
istered together with chemotherapy in order to prevent can-
cer cells from repairing the DNA damage induced by
chemotherapy itself. Biological agents can be grouped in two
main classes; both these classes have an increasing number
of drugs of potential interest and a complete review of them
will require a volume and it is beyond the scope of this paper.
Wethereforewillmentionthosethatappearmorepromising,
having in mind that, by the time our paper will appear, sev-
eral new products will be introduced in the clinical practice.
3.3. Monoclonal Antibodies (mAbs). Ideal drugs would be
antibodies against speciﬁc antigens on cancer cells that are
not cross-reactive with those on normal tissues. mAbs achi-
eve their therapeutic eﬀect through various mechanisms.
They can have direct eﬀects in inducing apoptosis or pro-
grammed cell death; they can block growth factor receptors,
eﬀectively arresting proliferation of tumor cells; they can
bring about antiidiotype antibody formation enhancing the
p a t i e n t ’ si m m u n er e s p o n s e[ 89, 90].
mAbs can be associated to other substance such as a
chemotherapy drug, radioactive particle, or a toxin in order
to selectively deliver them to a speciﬁc cancer cell.
The ﬁrst monoclonal antibody to receive FDA approval
wasrituximab,anantibodydirectedtotheCD20antigen[89,
90]. CD20 is a transmembrane protein whose intracellular
portion contains phosphorylation sequences for protein
kinase C, calmodulin, and casein kinase 2. Rituximab is
active against B-cell lymphoproliferative diseases [89] that
are the large majority of lymphoproliferative diseases [91].
When rituximab cross-links CD20 antigen, an increase in
intracellular calcium is observed. This increase appears to
activate the SER family of tyrosine kinases, resulting in fur-
ther phosphorylation of the CD20 inner cytoplasmic chain
and also phospholipase C-gamma. At the same time there
is an upregulation of C-myc and myb messenger ribonucle-
ic acid, an increase in adhesion molecule expression, and
anupregulationofMHCclassIIproteins.Theultimateresult
is caspase 3 activation, causing cell apoptosis.
Results of studies with rituximab alone as ﬁrst-line treat-
ment of low-grade non-Hodgkin’s lymphoma have been en-
couraging [92, 93], as well as inhibition of p38 kinase [94].
RituximabhasbeenalsocombinedwithconventionalCHOP
chemotherapy (cyclophosphamide, doxorubicin, vincristine,
and prednisone) for patients with intermediate grade or
diﬀuse large-cell non-Hodgkin’s lymphoma [95, 96].
Alemtuzumab is a mAb targeted at the CD52 antigen,
found on the surface of most chronic lymphocytic leukemia
(CLL) cells. It is particularly eﬃcient in chemotherapy-re-
sistant B-CLL. Binding of alemtuzumab to CD52 on target
cellsmaycausecelldeathby3diﬀerentmechanisms:comple-
ment activation, antibody-dependent cellular cytotoxicity,
and apoptosis [97, 98].
In addition, mAbs can be used to deliver a toxin, such as
the RFB4(dsFv)-PE38 (BL22), a recombinant immunotoxin
containingananti-CD22variabledomain(Fv)fusedtotrun-
cated pseudomonas exotoxin [99]. CD22 antigen is found
on the surface of hairy cell leukemia (HCL) cells. To target
relapsed/refractory HCL, immunotherapy has been devel-
oped using anti-CD25 and anti-CD22 recombinant immun-
otoxins, or rituximab alone or combined with purine ana-
logs. BL22 is now in phase I and II testing of relapsed/refrac-
tory HCL, achieving 47–61% complete remissions, several of
them ongoing after 9-10 years [100].
Hematological malignancies show a wide variety of sur-
face markers as potential target for mAbs targeting [91, 101–
103]. In comparison to hematological malignancies, solid
tumors have fewer speciﬁc targets for mAbs that are not
cross-reactive with antigens on normal tissues.
In 2006 the FDA approved trastuzumab, the ﬁrst mono-
clonal antibody for the treatment of a solid tumour, in HER2
overexpressing breast cancer [104]. Trastuzumab works in
several ways: downregulation of HER2 receptor expression;
inhibition of proliferation of human tumour cells that
over-express HER2 protein; enhancing immune recruitment
and antibody-dependent cell-mediated cytotoxicity (ADCC)
against tumour cells that overexpress HER2 protein, and
downregulation of angiogenesis factors. Trastuzumab also
increases the eﬀect of chemotherapy on breast cancer cells
(on the average the response rate rises from 50% up to 85%),
and it is currently used in combination with diﬀerent chem-
otherapy regimens in metastatic disease, in adjuvant and
neoadjuvant setting [105, 106].
It is important to point out that there are several eviden-
ces suggesting that blockade of signal transduction may not
be the only mechanism of action of mAbs since a potential
role of immunologic mechanisms in the therapeutic eﬃcacy
of ErbB-targeted mAbs (as opposed to TKI) has been report-
ed. Among the variables known to play a role in the anti-
tumor activity of TA-targeted mAbs, there is their ability to
mediate lysis of tumor cells in vitro by NK cells, monocytes,
and granulocytes in an ADCC way. The extent of lysis is in
turninﬂuencedbyseveralvariables,andthey,oratleastsome
of them, may contribute to the diﬀerential clinical response
of patients treated with mAbs-based immunotherapy [107].Clinical and Developmental Immunology 7
mAbs also bind complement, leading to direct cell toxicity,
known as complement-dependent cytotoxicity (CDC).
Cetuximab is mAb eﬀective for treatment of advanced
coloncancer in combination with 5-ﬂuorouracil, oxaliplatin,
or irinotecan chemotherapy. It is also useful in locally ad-
vanced head and neck squamous-cell carcinoma when com-
bined with radiotherapy or in recurrent head and neck can-
cer, combined with platinum-based chemotherapy [108].
Several papers have reported that the activity of cetux-
imab, as well as of panitumumab, is related to their link to
the epidermal growth factor (EGFR) which prevents cancer
cells from growing. In particular, it has been shown that
these mAbs are eﬀective only in patients whose cancer has no
mutation of K-RAS gene, the so-called wild-type sequence.
The mutation can be detected in about 40% of patients. The
K-RAS mutations keep the EGFR always active so that its
pathway can no longer be stopped by simply blocking the
receptor [109].
Other mAbs have the function to enhance T-cell activa-
tion by blocking CTLA-4, a major negative regulator of T-
cell-mediatedresponses.Aswediscussedpreviously,CTLA-4
isahomologofCD28thatfunctionsasaninhibitoryreceptor
for B7 costimulatory molecules expressed on mature APCs.
Anti-CTLA-4 mAbs with a much greater aﬃnity for CTLA-4
than B7 may provide a survival advantage compared to vac-
cines or chemotherapy alone [90]. On the basis of these pre-
clinical data, clinical trials have been initiated with two fully
human anti-CTLA-4 mAbs, with diﬀerent pharmacokinetic
and pharmacodynamic proﬁles.
Anti-CTLA4 blocking antibodies [110]a r ee ﬀective in
the treatment of malignant melanoma and may increase
Th17 cells in peripheral blood of patients with metastatic
melanoma. However, anti-CTLA-4 antibody therapy is asso-
ciated with autoimmune toxicity, due to the augmented cel-
lular proinﬂammatory activity, as consequence of the in-
crease of Th17 cells and of the inhibition of Tregs function
[17].
Tremelimumab is a human IgG2 anti-CTLA-4 mAb with
a serum half-life of approximately 22 days, the same reported
for endogenous human IgG2, which is currently under
evaluationatescalatingdoses(from3to15mg/kgeverythree
months) in several phase I studies in patients with metastatic
tumors such as pancreatic, breast [111] and renal cell car-
cinoma in combination with conventional therapies. As a
single agent, tremelimumab did not demonstrate a clinically
signiﬁcant activity in a phase II study of patients with re-
fractory metastatic CRC [112]; it generated durable tumor
responses in a phase I/II trial of patients with treated meta-
static melanoma [113], but it failed to produce a survival
advantage in a randomized phase III study compared to con-
ventional chemotherapy with dacarbazine or temozolomide
[20].
Ipilimumab is a fully human monoclonal antibody IgG1
with a shorter half-life, which was tested at a dose of
3mg/kg with or without dacarbazine and at 10mg/kg as
monotherapy every 3 weeks in several phase II studies in
metastatic melanoma patients showing a signiﬁcant activity
with durable remissions [114]. These results have been con-
ﬁrmed recently in the ﬁrst randomized phase 3 trial [115]
in patients with previously treated advanced melanoma with
ipilimumab signiﬁcantly prolonging median overall survival
both as a single agent (10.1 months; P<0.003) and com-
bined with a gp100 vaccine (10.0 months; P<0.001) com-
pared with vaccine control (6.4 months). Even more note-
worthy was the improvement in long-term survival at 24
months from 13.7% (gp100 alone) to 21.6% and 23.5% for
the combination and single ipilimumab, respectively [115].
In addition some patients who progressed after an initial
response (consisting of stable disease for more than six
months, partial or complete response) were rechallenged
within 28 days of documented progression with ipilimumab,
showing a 50% response rate [114]. This pattern of delayed
response is peculiar of anti-CTLA4 antibodies and is the
reason why novel immune-related response criteria were de-
veloped, according to which progressive disease is deﬁned as
an increase ≥25% in the sum of tumor diameters conﬁrmed
by two scans at least 4 weeks apart. However, anti-CTLA4
agentsalsoexhibitasevereproﬁleofadverseeventsincluding
severe rash, grade 3-4 enterocolitis, hypophysitis, hepatitis,
and more rarely, uveitis, pancreatitis, neuropathy, severe leu-
copenia, and red cell aplasia which are generally manageable
and reversible if recognized early and treated promptly with
corticosteroids [114]. Also ipilimumab produced encourag-
ing results in phase I trails for patients with hormone-refrac-
tory prostate cancer, ovarian cancer, and non-Hodgkin’s
lymphoma and in phase II study of patients with metastatic
clear cell renal carcinoma [114, 116]. It also significantly
increased progression-free survival after conventional chem-
otherapy with carboplatin and paclitaxel in patients with
untreated lung cancer [117]. On the basis of these data,
anti-CTLA4 monoclonal antibodies representone promising
strategy to support and enhance the patient’s natural antitu-
mor response.
3.4. Antiangiogenic mAbs. Antiangiogenic drugs are biologi-
cal therapies that stop tumors from creating their own blood
vessels. There are diﬀerent types of drugs that block blood
vessel growth, including drugs that prevent growth factors
fromreachingcancercells,drugsthatblockthegrowthfactor
inside the cell, and drugs that aﬀect signals between cells.
Vascularendothelialgrowthfactor(VEGF)isoneofthemain
proteins involved in angiogenesis [118, 119].
Bevacizumab, by blocking VEGF, can stop the receptors
from sending signals necessary for blood-vessel growing.
Once a receptor on a cell surface has been triggered and the
pathway inside the cell activated, only tyrosine kinase inhib-
itors (TKIs), such as Sunitinib, can block signals that trigger
the growth of new blood vessels.
Thalidomide is another antiangiogenic drug; even if its
mechanism of action is still not well known, it seems to in-
terfere with growth signals among cells. It is helpful for re-
fractory multiple myeloma.
3.5. Conjugated mAbs. As discussed above, mAbs may carry
other drugs or radiation directly to cancer cells. Mono-
clonal antibodies can be conjugated with anticancer drugs,
radioisotopes, other biologic response modiﬁers, or other
toxins. When the antibodies bind with antigen-bearing cells,8 Clinical and Developmental Immunology
Table 1: Summary of some of the most promising drugs currently under investigation, with their target molecule and more promising
diseases of application.





Melanoma∗,N o n - H o d g k i n ’ s
lymphoma, prostate cancer, renal
cell cancer
Rituximab CD20 B-cell lymphoproliferative
malignances
Alemtuzumab CD52 B-CLL
Trastuzumab HER2/neu Breast cancer
Cetuximab
Panitumumab EGFR CRC, head and neck cancer, and
others
Bevacizumab VEGF




Ibritumomab CD20 B-cell lymphoproliferative
malignances
Oncogene inhibitors Plexxikon BRAF Melanoma
Vaccines Sipuleucel-T APC presenting prostatic antigens Prostate cancer
TroVax APC presenting 5T4 epitope Advanced CRC, renal cell
carcinoma, prostate cancer
HSP90 inhibitors 17-AAG
geldanamycin HSP90 Various cancer
Abbreviations used in the table:
APC: antigen presenting Cell,
B-CLL: B-cell chronic lymphocytic leukemia,
CRC: coloRectal carcinoma,
EGFR: epidermal growth factor Receptor,
HCC: hepatocellular carcinoma,
HSP90: heat shock protein 90,
NSCLC: non-small-cell lung carcinoma,
VEGF: vascular epidermal growth factor,
∗This agent as most of the others may also be used in combination with TAA-based vaccines, cytokines, and chemotherapy.
they deliver their load of drug directly to the tumour. Tos-
itumomab and Ibritumomab are two new promising mon-
oclonal antibodies, conjugated with radioisotopes, targeting
CD20, that are still under investigation.
Antibody directed enzyme prodrug therapy (ADEPT) is
a selective way for carrying an anticancer drug directly to
cancer cells. The treatment is given in 2 steps. First, a mAb
provided with an enzyme attached to it is administered;
then, an inactive anticancer drug called a prodrug is given.
When the prodrug and the enzymes meet in the cancer cell,
the pro drug becomes active. This approach is still under
investigation [120].
4. Conclusions
While the drugs reported above have clearly shown antitu-
mor activity (a summary of some of the most promising is
reported in Table 1), it is still possible to use these drugs
in combination with TAA-based vaccines, cytokines, and
chemotherapy.
While there are numerous immunotherapies with poten-
tial for destruction of human cancers, we are tempted to
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